Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05789056 · ClinicalTrials.gov registry record · Phase 2
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
A Phase 2 study of Netherton Syndrome, sponsored by Quoin Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT05789056: Recruiting Phase 2 study of Netherton Syndrome, sponsored by Quoin Pharmaceuticals.
NCT05789056 is a Phase 2 study of Netherton Syndrome that is actively recruiting participants, run by Quoin Pharmaceuticals. The registered enrollment target is 20 participants, below the 25-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (20% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05789056, a Phase 2 study of Netherton Syndrome, is actively recruiting participants, sponsored by Quoin Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Primary Outcome
Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline. The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.
Conditions Studied
Interventions
- DRUG QRX003, 4% Lotion
Study Locations (4)
California
- Site #1 - San Diego
Indiana
- Site #4 - Indianapolis
Massachusetts
- Site #5 - Quincy
Texas
- Site #2 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
What NCT05789056 shows while recruiting
NCT05789056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 25-participant average among 6 other Netherton Syndrome trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Netherton Syndrome appearing as the primary indexed condition, and to 1 intervention - of which QRX003, 4% Lotion is the first listed.
NCT05789056 reports a single indexed study location in California, Indiana, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05789056 about?
NCT05789056 is a clinical study titled "Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome". To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
What is the current status of trial NCT05789056?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-03-14. Estimated completion is 2025-12-30.
What conditions does trial NCT05789056 study?
This clinical trial studies the following conditions: Netherton Syndrome.
What interventions are being tested in trial NCT05789056?
The interventions under investigation include: QRX003, 4% Lotion (DRUG).
Who is sponsoring clinical trial NCT05789056?
This trial is sponsored by Quoin Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05789056 being conducted?
This trial has 4 study locations across California, Indiana, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Netherton Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
The Efficacy and Safety of Secukinumab in Patients With Ichthyoses
COMPLETED · Phase 2
-
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
RECRUITING · Phase 1
-
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
RECRUITING · Phase 1
-
Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI